Clinical study on ultrasound-guided percutaneous microwave ablation for malignant tumor

Objective To evaluate the feasibility and efficiency of ultrasound-guided percutaneous microwave coagulation therapy for malignant tumor. Methods A total of 373 cases of solid carcinoma, which included 340 cases of hepatic cancer, 17 cases of lung cancer, 13 cases of bone tumor, 2 cases of kidney tumor and 1 case of adrenal tumor, were received ultrasound-guided percutaneous microwave ablation therapy. Results After the treatment, all lesions were decreased in size and blood flow in nodules disappeared. Repeated biopsy in 27 patients showed complete necroses of tumors. There was no enhancement in the tumor on enhanced CT scans. All patients were better than before, their symptoms were relief or disappearance, and the appetite were increase significantly. The effective rate (CR+PR) was 83.2%, and the 1, 2, 3, 5 years survival rates were 88.8%, 68.5%, 60.9% and 38.6% respectively in the small hepatic cancer (≤5 cm), whereas in the large hepatic cancer (5 cm), the effective rate (CR+PR) was 61.9%, and the 1, 2, 3, 5 years survival rates were 67.8%, 51.7%, 39.8%, and 24.6%, respectively. The 1, 2, 3, 5 years survival rates in microwave ablation and transcatheter arterial embolization were 88.6%, 71.4%, 60.0% and 42.9% respectively. The effective rates (CR+PR) in patients with lung cancer and bone tumor were 64.7% and 100%. Patients felt the pain disappeared or remissive and the limbs functions were recovered in the bone tumor. There were no severe complications in the patients with malignant tumor by ultrasound-guided percutaneous microwave ablation therapy. Conclusion Ultrasound-guided percutaneous microwave ablation therapy is a safe, effective and feasible method for solid carcinoma, such as hepatic cancer, lung cancer, bone tumor.